Impact assessment of onchocerciasis through lymphatic filariasis transmission assessment surveys using Ov-16 rapid diagnostic tests in Sierra Leone.

Publisher: BioMed Central Country of Publication: England NLM ID: 101462774 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-3305 (Electronic) Linking ISSN: 17563305 NLM ISO Abbreviation: Parasit Vectors Subsets: MEDLINE

Original Publication: London : BioMed Central

Elephantiasis, Filarial*/diagnosis ; Elephantiasis, Filarial*/drug therapy ; Elephantiasis, Filarial*/epidemiology ; Onchocerciasis*/diagnosis ; Onchocerciasis*/drug therapy ; Onchocerciasis*/epidemiology; Child ; Female ; Humans ; Male ; Immunoglobulin G ; Ivermectin/therapeutic use ; Prevalence ; Rapid Diagnostic Tests ; Seroepidemiologic Studies ; Sierra Leone/epidemiology ; Child, Preschool ; Adolescent ; Young Adult

Background: Onchocerciasis is endemic in 14 of Sierra Leone's 16 districts with high prevalence (47-88.5%) according to skin snips at baseline. After 11 rounds of mass treatment with ivermectin with good coverage, an impact assessment was conducted in 2017 to assess the progress towards eliminating onchocerciasis in the country.
Methods: A cluster survey was conducted, either integrated with lymphatic filariasis (LF) transmission assessment survey (TAS) or standalone with the LF TAS sampling strategy in 12 (now 14) endemic districts. Finger prick blood samples of randomly selected children in Grades 1-4 were tested in the field using SD Bioline Onchocerciasis IgG4 rapid tests.
Results: In total, 17,402 children aged 4-19 years in 177 schools were tested, and data from 17,364 children aged 4-14 years (14,230 children aged 5-9 years) were analyzed. Three hundred forty-six children were confirmed positive for Ov-16 IgG4 antibodies, a prevalence of 2.0% (95% CI 1.8-2.2%) in children aged 4-14 years with prevalence increasing with age. Prevalence in boys (2.4%; 95% CI 2.1-2.7%) was higher than in girls (1.6%; 95% CI 1.4-1.9%). There was a trend of continued reduction from baseline to 2010. Using data from children aged 5-9 years, overall prevalence was 1.7% (95% CI 1.5-1.9%). The site prevalence ranged from 0 to 33.3% (median prevalence = 0.0%): < 2% in 127 schools, 2 to < 5% in 34 schools and ≥ 5% in 16 schools. There was a significant difference in average prevalence between districts. Using spatial analysis, the Ov-16 IgG4 antibody prevalence was predicted to be < 2% in coastal areas and in large parts of Koinadugu, Bombali and Tonkolili Districts, while high prevalence (> 5%) was predicted in some focal areas, centered in Karene, Kailahun and Moyamba/Tonkolili.
Conclusions: Low Ov-16 IgG4 antibody prevalence was shown in most areas across Sierra Leone. In particular, low seroprevalence in children aged 5-9 years suggests that the infection was reduced to a low level after 11 rounds of treatment intervention. Sierra Leone has made major progress towards elimination of onchocerciasis. However, attention must be paid to those high prevalence focal areas.
(© 2024. The Author(s).)

J Infect Dis. 2006 Jul 15;194(2):216-21. (PMID: 16779728)
Trop Med Parasitol. 1992 Jun;43(2):75-9. (PMID: 1519029)
Clin Vaccine Immunol. 2015 Aug;22(8):896-901. (PMID: 26018537)
PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005314. (PMID: 28114304)
Parasit Vectors. 2012 Jan 11;5:10. (PMID: 22236419)
Int Health. 2011 Jun;3(2):69-74. (PMID: 24038179)
Trop Doct. 2003 Oct;33(4):209-14. (PMID: 14620423)
Ann Trop Med Parasitol. 2002 Apr;96(3):283-96. (PMID: 12061975)
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:23-4. (PMID: 18718150)
J Infect Dis. 2000 Dec;182(6):1796-9. (PMID: 11069258)
Ann Trop Med Parasitol. 1995 Feb;89(1):63-72. (PMID: 7741596)
Bull World Health Organ. 1967;37(3):415-30. (PMID: 5301384)
Parasit Vectors. 2017 Mar 23;10(1):154. (PMID: 28335815)
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:19-22. (PMID: 18718149)
PLoS Negl Trop Dis. 2017 Oct 3;11(10):e0005884. (PMID: 28972982)
Parasit Vectors. 2014 Jul 22;7:325. (PMID: 25053266)
Lancet Glob Health. 2021 Apr;9(4):e489-e551. (PMID: 33607016)
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:13-7. (PMID: 18718148)
Parasit Vectors. 2018 Jun 4;11(1):334. (PMID: 29866207)
PLoS One. 2013 Jul 23;8(7):e69231. (PMID: 23935960)
Parasit Vectors. 2010 Dec 16;3:120. (PMID: 21162751)
PLoS Negl Trop Dis. 2012;6(9):e1825. (PMID: 23029586)
Parasit Vectors. 2016 Jun 13;9(1):338. (PMID: 27296630)
PLoS Negl Trop Dis. 2020 Dec 28;14(12):e0008877. (PMID: 33370270)
Am J Trop Med Hyg. 2022 Aug 1;:. (PMID: 35914689)
Infect Dis Poverty. 2018 Apr 6;7(1):30. (PMID: 29628019)
Pathogens. 2020 Jun 02;9(6):. (PMID: 32498284)
PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009604. (PMID: 34310602)
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497. (PMID: 19621091)

Keywords: Antibody; Onchocerciasis; Ov-16; Prevalence; Sierra Leone

0 (Immunoglobulin G)
70288-86-7 (Ivermectin)

Date Created: 20240312 Date Completed: 20240313 Latest Revision: 20240315

20240315

PMC10926616

10.1186/s13071-024-06198-5

38468307